Cardiac arrhythmias in hospitalized patients with COVID-19: A prospective observational study in the western United States.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 12 08 2020
accepted: 12 12 2020
entrez: 28 12 2020
pubmed: 29 12 2020
medline: 12 1 2021
Statut: epublish

Résumé

Arrhythmias have been reported frequently in COVID-19 patients, but the incidence and nature have not been well characterized. Patients admitted with COVID-19 and monitored by telemetry were prospectively enrolled in the study. Baseline characteristics, hospital course, treatment and complications were collected from the patients' medical records. Telemetry was monitored to detect the incidence of cardiac arrhythmias. The incidence and types of cardiac arrhythmias were analyzed and compared between survivors and non-survivors. Among 143 patients admitted with telemetry monitoring, overall in-hospital mortality was 25.2% (36/143 patients) during the period of observation (mean follow-up 23.7 days). Survivors were less tachycardic on initial presentation (heart rate 90.6 ± 19.6 vs. 99.3 ± 23.1 bpm, p = 0.030) and had lower troponin (peak troponin 0.03 vs. 0.18 ng/ml. p = 0.004), C-reactive protein (peak C-reactive protein 97 vs. 181 mg/dl, p = 0.029), and interleukin-6 levels (peak interleukin-6 30 vs. 246 pg/ml, p = 0.003). Sinus tachycardia, the most common arrhythmia (detected in 39.9% [57/143] of patients), occurred more frequently in non-survivors (58.3% vs. 33.6% in survivors, p = 0.009). Premature ventricular complexes occurred in 28.7% (41/143), and non-sustained ventricular tachycardia in 15.4% (22/143) of patients, with no difference between survivors and non-survivors. Sustained ventricular tachycardia and ventricular fibrillation were not frequent (seen only in 1.4% and 0.7% of patients, respectively). Contrary to reports from other regions, overall mortality was higher and ventricular arrhythmias were infrequent in this hospitalized and monitored COVID-19 population. Either disease or management-related factors could explain this divergence of clinical outcomes, and should be urgently investigated.

Identifiants

pubmed: 33370347
doi: 10.1371/journal.pone.0244533
pii: PONE-D-20-25283
pmc: PMC7769280
doi:

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244533

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL135866
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Circ Res. 2020 May 8;126(10):1443-1455
pubmed: 32252591
N Engl J Med. 2009 Apr 9;360(15):1526-38
pubmed: 19357408
Heart Rhythm. 2019 May;16(5):793-801
pubmed: 30476544
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Heart Rhythm. 2020 Sep;17(9):1439-1444
pubmed: 32585191
Resuscitation. 2020 Jun;151:18-23
pubmed: 32283117
J Am Coll Cardiol. 2020 Mar 10;75(9):1046-1057
pubmed: 32138965
Lancet Public Health. 2020 Oct;5(10):e536-e542
pubmed: 32950075
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Card Electrophysiol Clin. 2015 Jun;7(2):269-81
pubmed: 26002391
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452

Auteurs

Jae Hyung Cho (JH)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Ali Namazi (A)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Richard Shelton (R)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Archana Ramireddy (A)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Ashkan Ehdaie (A)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Michael Shehata (M)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Xunzhang Wang (X)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Eduardo Marbán (E)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Sumeet S Chugh (SS)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Eugenio Cingolani (E)

Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH